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Abstract Background: Transplantation in patients with
inborn errors of metabolism (IEM) may be used as rescue
therapy for acute decompensation, organ replacement, or
disease-modifying therapy. We sought to quantify the use of
transplantation in adults with IEM.
Methods: A 10-question online survey was sent through
the email list of adult IEM physicians maintained by the
Society for the Study of Inborn Errors of Metabolism and
posted on the website of the Society of Inherited Metabolic
Diseases.
Results: Thirteen centers from five continents
responded. These centers, ranging in size from <50 adult
patients (three centers) to >500 (two centers), reported 57
adult patients who had undergone transplantation. 29/57
(51 %) came from the two largest centers and 27/57(47 %)
were renal transplants for Fabry disease (FD). Only seven
transplants were identified as being done for acute
decompensation. Eight of thirteen centers had not had
patients with IEM passed over on the transplant list but
four of these eight had not referred a patient for trans-
plantation. 4/13 centers had patients passed over on the
transplant list and reasons cited included: (a) transplant
team not comfortable with underlying disease, (b) cogni-
tive impairment in patient raised concerns about compli-
ance, (c) multisystem disease makes single organ
transplantation inappropriate, and (d) not at enough risk
of life-threatening decompensation.
Conclusions: Excluding renal transplantation for FD,
there is low use of transplantation in adults with IEM. Some
barriers to transplantation reported by adult centers could be
improved with development of educational and manage-
ment modules for both transplant and metabolic programs.
Introduction
Organ transplantation has been used as a therapeutic
modality for many inborn errors of metabolism (IEM).
Transplantation can be done to provide organ replacement
therapy as in the case of patients with renal failure from
Fabry disease (FD) (Weidemann et al. 2010) or methyl-
malonic aciduria (MMA) (McGuire et al. 2008). It can be a
life-saving therapy for patients with acute metabolic
decompensation from unstable conditions like maple syrup
urine disease (Mazariegos et al. 2012) and urea cycle
defects (UCD) (Morioka et al. 2005). Finally, it can be used
to modify the disease course of progressive IEMs, particu-
larly those with involvement of the central nervous system
(such as Krabbe disease, metachromatic leukodystrophy,
adrenoleukodystrophy, and mucopolysaccharidoses) where
alternative treatment strategies are limited (Boelens et al.
2010). Recently, there has been a move to increase the
availability of adult specialty clinics to allow the transition
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of patients from the pediatric to the adult health care
system. We sought to quantify the use of transplantation as
a therapeutic modality in adults with IEM.
Methods
A 10-question online survey was sent out through an email
list maintained by a representative of the Society for the
Study of Inborn Errors of Metabolism (SSIEM) of
physicians who identify their interest as the care of adults
with IEM. The survey link was also posted on the Society
for Inherited Metabolic Disorders (SIMD) website. The
survey asked for details of center size (number of adult
patients followed), location, and if the center had referred
patients for transplantation (and, if so, indications for the
procedure). Centers were also asked if they had referred a
patient for transplantation who subsequently had been
rejected by the transplant team or passed over while on
the transplant waiting list (and, if so, indications for this
decision). The survey was available for completion for
2.5 months before data were collected for analysis.
Results
Thirteen centers from five continents responded and details
of their responses are shown in Table 1. These centers,
ranging in size from <50 adult patients (three centers) to
>500 (two centers), reported 57 adult patients who had
undergone organ transplantation. 29/57 (51 %) of the
transplant recipients were from the two largest centers and
27/57(47 %) of transplants were renal transplants for Fabry
disease (FD). As expected, most transplants (38/57 or
67 %) were performed because of organ failure. Surpris-
ingly few transplants were performed for acute metabolic
decompensation (porphyria N ¼ 2, UCD N ¼ 5, four of
which were at a single center), given that these centers
collectively follow thousands of patients. A small number
transplants were performed in patients with the intention of
modification of disease course (metachromatic leukodys-
trophy (2), and Krabbe (1)) although, as the reasons for
transplantation were not specified in all cases (adrenoleu-
kodystrophy N ¼ 6, GSD N ¼ 1, and MNGIE N ¼ 1), it is
possible that some of the remaining cases were transplanted
with the intention of modifying the disease course. One
patient received a bone marrow transplant for myelodys-
plasia in the context of Gaucher disease.
Eight of 13 centers had not had patients with IEM
passed over while on the transplant list but four of these
eight had never referred a patient for transplantation so this
may represent a referral bias. 4/13 centers had patients who
were passed over while on the transplant list and reasons
cited included: (a) transplant team not comfortable with
underlying disease, (b) cognitive impairment in patient
raised concerns about compliance with post-transplant care,
(c) involvement of other organ systems by the IEM made
single organ transplantation inappropriate, and (d) candi-
date considered to be not at enough risk of life-threatening
decompensation to justify organ transplantation.
Discussion
Our study, the first to explore this area, reveals that
transplantation for acute metabolic decompensation, or as
a disease-modifying therapy, is infrequent in centers
looking after adults with IEM. The majority of transplants
were done for end-stage renal disease and such transplants
(which are primarily organized by consultant nephrologist
rather than the IEM center) are done for symptom
management (such as end-stage renal disease regardless of
cause) rather than to modify disease course. Only seven
patients were reported to have received transplantation for
acute metabolic decompensation (in relatively common
IEM such as porphyria and UCD) despite the fact that the
13 centers who responded to our survey were caring for
thousands of adults with IEM. In considering the barriers to
transplantation in this patient population, they can be
categorized into four groups: (a) patient-specific factors,
(b) lack of evidence on treatment outcomes, (c) factors
resulting from organ allocation policies, and (d) factors
specific to the metabolic and transplant programs.
1. Patient-specific factors – when comparing pediatric
patients with IEM with adults, it may be reasonable to
assume that those patients who survive to adulthood
have less severe disease and therefore are less likely to
require a transplant for survival. While it is true that
the survival rate of patients presenting over the age of
12 years with conditions like urea cycle defects and
symptomatic hyperammonemia is much higher than
those with earlier onset presentations (Enns et al.
2007), mortality rate is high in patients with severe
symptoms of an IEM regardless of age. For example,
25 % of female OTC patients who present with coma
(Enns et al. 2007) and 29 % of adults with acute
presentations of MCAD (Lang 2009) will die. These
publications (Enns et al. 2007, Lang 2009) reflect a
publication bias in that they focus on symptomatic
cases and many adult patients with IEM such as
MCAD will be asymptomatic. However, it is clear
from these publications that adults with severe symp-
toms of their IEM may have poor outcomes. Impor-
tantly, the IEM literature suggests that earlier
transplantation results in improved neurologic out-




























































































































































































































































































































































































































































































































































































































































































































































































































































et al. 2004), maple syrup urine disease (Mazariegos
et al. 2012), and some lysosomal storage diseases
(Wynn et al. 2009). Finally, the burden of comorbid
disease which may precipitate metabolic decompensa-
tion is higher in adults than in children (Summar et al.
2005; Lang 2009). These data suggest that severity of
symptoms, rather than age of symptom onset, should be
the main factor in considering transplantation.
2. Lack of evidence on therapy outcomes – there are no
systematic studies available which assess the efficacy of
transplantation in adults with IEM. Adults are included
in many case series (for example, see Morioka et al.
2005; Summar et al. 2005; Mazariegos et al. 2012) and
there is not a suggestion in these series that the outcomes
are worse for the adults than for the children but data are
not analyzed separately to make that determination. Such
analysis is required as the risks of transplantation in
adults (who have comorbid disease) will differ from
those in children. Also, data on natural history of many
IEM in adults are completely lacking making it difficult
for clinicians to weigh the risks and benefits of
transplantation. Finally, the lack of information on
prognostic factors in adults makes it difficult to ascertain
which patients are most likely to benefit from organ
allocation. A registry which collects data on adults with
IEM who have undergone transplantation might be one
strategy by which evidence could be collected on the
outcomes of transplantation in these patients.
3. Organ allocation policies – organs from cadaveric
donors are a limited resource and existing organ
allocation protocols, created to prioritize patients with
end-stage organ failure, may disadvantage patients with
IEM. If we consider liver transplantation, both the
United Network for Organ Sharing (www.UNOS.org)
and Eurotransplant (www.Eurotransplant.org) use the
Model for End-Stage Liver Disease (MELD) scoring
system to prioritize patients for liver transplant. The
MELD score is based on INR, creatinine, and bilirubin
so a patient without a defect in hepatic synthetic
function, i.e., without end-stage cirrhosis, would have a
low MELD score. It became clear that the MELD score
does not adequately reflect the need for transplantation
in some conditions including hepatocellular carcinoma,
and IEM (Bernardi et al. 2011). To address this problem,
a working group developed a short list of genetic
conditions (including familial hyperoxaluria and familial
amyloid polyneuropathy) to which exceptions to the
MELD system are accepted (Freeman et al. 2006) and
“unusual metabolic diseases” are included, although few
are named as exceptions. A “Share-15” policy was
adopted in the US (where 15 % of the organs were to be
shared amongst patients with MELD scores below 15)
but as programs used these organs for patients on their
list with higher MELD scores (Washburn et al. 2011),
this did not have the desired effect. In our study, some
centers had experienced patients being withdrawn from
the transplant list because they were not “sick enough”
and this is understandable when one considers the
limitations and restrictions of the current allocation
process. Finally, as patients with IEM have a low
incidence of comorbid disease, they might be expected
to have better long-term survival than patients with other
diseases like chronic hepatitis who are at risk of
numerous extra-hepatic morbidities or recurrence of the
primary liver disease (e.g., hepatitis C where graft
recurrence is almost universal). Indeed, patient survival
in large series patients with UCD undergoing liver
transplantation was significantly higher than in patients
undergoing liver transplantation for other reasons at that
same center (Morioka et al. 2005). Age and need for life
support are two powerful predictors of survival after
liver transplantation (Dutkowski et al. 2011) and patients
with IEM are likely to be younger, to be stable between
episodes of decompensation, and to have fewer comor-
bid diseases than patients with end-stage liver disease or
cancer and thus might be predicted to have improved
survival after receiving liver transplantation relative to
those with other diseases such as chronic hepatitis or
hepatocellular carcinoma. Modifications to the allocation
process could be made to adjust for these disparities and
allow patients with IEM to be appropriately prioritized
within the organ allocation ranking system. Such
modifications could weight variables such as:
(a) likelihood of recurrent acute decompensation,
(b) risk of neurological injury with recurrent decompen-
sation, and (c) expected life span after transplantation
(to reflect age and comorbid diseases).
4. Program-specific factors – in our survey, 5/13 centers
had not referred a patient for transplantation. Half of all
the transplants reported in our survey were renal
transplants for Fabry disease, a situation in which one
could expect that the referral for transplantation would
arise not from the metabolic center but from the
nephrologist caring for the patient with end-stage renal
disease. In centers that had referred patients for
transplant assessment, patients were sometimes rejected
because the transplant team was not familiar with the
condition. This suggests that education of both meta-
bolic and transplant centers about the use of transplan-
tation in IEM, and ongoing discussion regarding
referred patients and potential patient referrals, may
increase the rate of referrals to transplant programs.
Also, qualitative research which evaluated the function-
ing of transplant program committees at different
centers (Volk et al. 2011) suggested subjective param-
eters such as the perception that the patient was “too
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well” or concerns about psychosocial barriers including
psychiatric disease and social supports affected deci-
sions made by the program committee as to whether or
not to list the patient for transplantation. In our survey,
metabolic centers had experienced patients being
rejected or passed over because they were perceived
to be “too well” (even though they may be at risk of
dying or neurologic compromise with the next disease
exacerbation) or due to concerns about compliance with
post-transplant immunosuppressive medications due to
cognitive impairment. However, patients with IEM,
even with cognitive impairment, may be capable of,
and familiar with, following a very complex regime of
tight nutritional control, use of metabolic formulae, and
multiple medications and, in such patients, a transplant,
by relaxing their dietary restrictions, may actually make
it easier for them to comply with a treatment program.
Thus, guidelines and education around the role that
these subjective factors play in making a decision
around listing a patient for transplantation may be
helpful for transplant programs. Also, education, as
well as a realization for the need for advocacy on behalf
of these patients, would be helpful for metabolic
centers to more effectively address these valid if
subjective concerns which influence transplant program
committee internal decisions.
Our study is limited by participation bias. We were
interested in the perceptions of physicians caring for adults
with IEM about transplantation and this study was not
intended to be a survey of transplant outcomes. We
recognize that not all centers caring for adults with IEM
may have received the link to the survey and we have no
way of ascertaining how many centers which did receive
the link to the survey chose not to participate. Also, we
cannot ensure that those centers who did respond included
all patients under their care who had received transplants.
Further, we cannot exclude that the study was free of the
nonresponse or voluntary response bias that may have
reflected a physicians experience or lack of experience with
transplantation in their centers. However, despite these
sources of potential bias inherent to any survey sampling,
we believe that this study has highlighted some of the
factors which IEM physicians feel may limit a patient’s
access to transplantation and may be an important starting
point to further investigate barriers to the use of transplan-
tation in the adult population with IEM.
Conclusions
The use of transplantation for acute metabolic decompen-
sation or to modify the disease course in adults with IEM is
uncommon. There is an urgent need to collect data on the
outcomes of adult patients with IEM who undergo
transplantation so as to allow clinicians to define prognostic
factors and the risk:benefit ratio of considering organ
transplantation for some indications. Some of the barriers
to the use of transplantation may also be modified through
the use of educational materials for transplant and meta-
bolic programs and evaluation of guidelines which underlie
organ allocation processes.
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Take Home Message
Barriers exist to the use of transplantation as disease-
modifying therapy in adults with IEM.
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